source
- FDA holds Type A meeting with Atara after CRL issued for tabelecleucel in EBV-positive PTLDThe FDA and Atara Biotherapeutics met in a Type A meeting to discuss the complete response letter (CRL) that the agency issued for the biologics license application of tabelecleucel, a therapy for…
- Entrada's Duchenne drug shows disappointing early data, shares tumbleEntrada disclosed initial results from a low‑dose version of its exon‑44 skipping therapy for Duchenne muscular dystrophy. The data, collected from six patients, failed to meet the company’s expect…